Literature DB >> 11238852

Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies.

Q Mao1, S C Ray, O Laeyendecker, J R Ticehurst, S A Strathdee, D Vlahov, D L Thomas.   

Abstract

When chronic hepatitis C virus (HCV) infections are complicated by acquisition of human immunodeficiency virus (HIV), liver disease appears to accelerate and serum levels of HCV RNA may rise. We hypothesized that HIV might affect the HCV quasispecies by decreasing both complexity (if HIV-induced immunosuppression lessens pressure for selecting HCV substitutions) and the ratio of nonsynonymous (d(N)) to synonymous (d(S)) substitutions, because d(N) may be lower (if there is less selective pressure). To test this hypothesis, we studied the evolution of HCV sequences in 10 persons with chronic HCV infection who seroconverted to HIV and, over the next 3 years, had slow or rapid progression of HIV-associated disease. From each subject, four serum specimens were selected with reference to HIV seroconversion: (i) more than 2 years prior, (ii) less than 2 years prior, (iii) less than 2 years after, and (iv) more than 2 years after. The HCV quasispecies in these specimens was characterized by generating clones containing 1 kb of cDNA that spanned the E1 gene and the E2 hypervariable region 1 (HVR1), followed by analysis of clonal frequencies (via electrophoretic migration) and nucleotide sequences. We examined 1,320 cDNA clones (33 per time point) and 287 sequences (median of 7 per time point). We observed a trend toward lower d(N)/d(S) after HIV seroconversion in 7 of 10 subjects and lower d(N)/d(S) in those with rapid HIV disease progression. However, the magnitude of these differences was small. These results are consistent with the hypothesis that HIV infection alters the HCV quasispecies, but the number of subjects and observation time may be too low to characterize the full effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238852      PMCID: PMC114119          DOI: 10.1128/JVI.75.7.3259-3267.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.

Authors:  U Kumar; J Monjardino; H C Thomas
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

2.  Maintaining the integrity of human immunodeficiency virus sequence databases.

Authors:  G H Learn; B T Korber; B Foley; B H Hahn; S M Wolinsky; J I Mullins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion.

Authors:  W M Barnes
Journal:  Gene       Date:  1992-03-01       Impact factor: 3.688

4.  Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain.

Authors:  K E Sherman; C Andreatta; J O'Brien; A Gutierrez; R Harris
Journal:  Hepatology       Date:  1996-04       Impact factor: 17.425

5.  Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study.

Authors:  M E Eyster; L S Diamondstone; J M Lien; W C Ehmann; S Quan; J J Goedert
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-06

6.  Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study.

Authors:  J L Gerberding
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

7.  Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.

Authors:  D L Thomas; J W Shih; H J Alter; D Vlahov; S Cohn; D R Hoover; L Cheung; K E Nelson
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

8.  Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.

Authors:  M E Eyster; M W Fried; A M Di Bisceglie; J J Goedert
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

9.  Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections.

Authors:  K E Sherman; J O'Brien; A G Gutierrez; S Harrison; M Urdea; P Neuwald; J Wilber
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

10.  Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md.

Authors:  K E Nelson; D Vlahov; L Solomon; S Cohn; A Muñoz
Journal:  Arch Intern Med       Date:  1995-06-26
View more
  17 in total

1.  Seronegative hepatitis C virus infection in a child infected via mother-to-child transmission.

Authors:  Ariane Larouche; Geneviève Gaëtan; Nabil El-Bilali; Mathieu Quesnel-Vallières; Steven R Martin; Fernando Alvarez; Naglaa H Shoukry; Hugo Soudeyns
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV.

Authors:  Jason T Blackard; Gang Ma; Satarupa Sengupta; Christina M Martin; Eleanor A Powell; M Tarek Shata; Kenneth E Sherman
Journal:  J Med Virol       Date:  2014-04-30       Impact factor: 2.327

3.  Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Authors:  Ana Maria Contreras; Yoichi Hiasa; Wenping He; Adam Terella; Emmett V Schmidt; Raymond T Chung
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

4.  Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.

Authors:  Cassandra B Jabara; Fengyu Hu; Katie R Mollan; Sara E Williford; Prema Menezes; Yan Yang; Joseph J Eron; Michael W Fried; Michael G Hudgens; Corbin D Jones; Ronald Swanstrom; Stanley M Lemon
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression.

Authors:  Dale M Netski; Qing Mao; Stuart C Ray; Robert S Klein
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

6.  Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.

Authors:  William O Osburn; Anna E Snider; Brittany L Wells; Rachel Latanich; Justin R Bailey; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2014-04-29       Impact factor: 17.425

7.  Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART).

Authors:  Tomasz Laskus; Jeffrey Wilkinson; Roksana Karim; Wendy Mack; Marek Radkowski; Marina deGiacomo; Jonathan Nasseri; Zhi Chen; Jiaao Xu; Andrea Kovacs
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

Review 8.  Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence.

Authors:  Kelly P Burke; Andrea L Cox
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

9.  Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis.

Authors:  John R Ticehurst; Fayez M Hamzeh; David L Thomas
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

10.  Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons.

Authors:  Zhi Liu; Dale M Netski; Qing Mao; Oliver Laeyendecker; John R Ticehurst; Xiao-Hong Wang; David L Thomas; Stuart C Ray
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.